Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ProPhase LabsPRPH -16.46% 3-Year Share Buyback Ratio is -76.90 as of Mar. 2026. The stock has 5 warning signs investors should review. Among 173 Medical Diagnostics & Research companies, ProPhase Labs ranks worse than 93.64% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. ProPhase Labs's current 3-Year Share Buyback Ratio was -76.90%.
The historical rank and industry rank for ProPhase Labs's 3-Year Share Buyback Ratio or its related term are showing as below:
PRPH'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -76.9 Med: -3.1 Max: 12.2
Current: -76.9
During the past 13 years, ProPhase Labs's highest 3-Year Share Buyback Ratio was 12.20%. The lowest was -76.90%. And the median was -3.10%.
PRPH's 3-Year Share Buyback Ratio is ranked worse than 93.64% of 173
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.4
vs PRPH: -76.90
ProPhase Labs (OTCPK:PRPH) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
ProPhase Labs 3-Year Share Buyback Ratio Related Terms
PRPH vs IDTA, NSTM, NOTVQ: 3-Year Share Buyback Ratio Comparison
For the Diagnostics & Research subindustry, ProPhase Labs's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProPhase Labs 3-Year Share Buyback Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where ProPhase Labs's 3-Year Share Buyback Ratio falls into.
ProPhase Labs 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -76.90 mean?
ProPhase Labs (PRPH) has a 3-Year Share Buyback Ratio of -76.90 as of Mar. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for ProPhase Labs and its competitors. According to the industry distribution chart, ProPhase Labs ranks #162 out of 173 companies in the Medical Diagnostics & Research industry, placing it in the top 93.6%.
Is ProPhase Labs' 3-Year Share Buyback Ratio too high?
ProPhase Labs' current 3-Year Share Buyback Ratio is -76.90. Based on the distribution chart, ProPhase Labs ranks #162 out of 173 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does ProPhase Labs' 3-Year Share Buyback Ratio compare to IDTA and NSTM?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #162 out of 173 companies for 3-Year Share Buyback Ratio. This places ProPhase Labs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Medical Diagnostics & Research company?
A good 3-Year Share Buyback Ratio depends on the Medical Diagnostics & Research industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for ProPhase Labs and its competitors. ProPhase Labs's current 3-Year Share Buyback Ratio is -76.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.91, compared to a current price of $0.04 — trading 95.4% below its estimated fair value. The current 3-Year Share Buyback Ratio is -76.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current 3-Year Share Buyback Ratio is -76.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPH has been successfully added to your 
